Spruce Biosciences, Inc. Common Stock (SPRB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Spruce Biosciences, Inc. Common Stock (SPRB) has a cash flow conversion efficiency ratio of -0.264x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.12 Million) by net assets ($83.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Spruce Biosciences, Inc. Common Stock market cap and net worth for the company's overall valuation and market capitalisation.
Spruce Biosciences, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Spruce Biosciences, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Spruce Biosciences, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spruce Biosciences, Inc. Common Stock ranked by their cash flow conversion efficiency. See how well can Spruce Biosciences, Inc. Common Stock service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vytrus Biotech S.A.
MC:VYT
|
0.022x |
|
Nynomic AG
F:M7U
|
-0.045x |
|
YESASIA HOLDINGS LTD
F:4CM
|
N/A |
|
Greystone Housing Impact Investors LP
NYSE:GHI
|
0.000x |
|
Gordon Auto Body Parts Co Ltd
TW:1524
|
0.088x |
|
Bonny Worldwide Ltd
TW:8467
|
-0.005x |
|
Chialin Precision Industrial Co Ltd
TWO:3310
|
-0.028x |
|
HAPPY BELLY FOOD GRO.INC.
F:W3J
|
N/A |
Annual Cash Flow Conversion Efficiency for Spruce Biosciences, Inc. Common Stock (2018–2025)
The table below shows the annual cash flow conversion efficiency of Spruce Biosciences, Inc. Common Stock from 2018 to 2025. View latest Spruce Biosciences, Inc. Common Stock stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $42.52 Million | $-33.33 Million | -0.784x | +59.63% |
| 2024-12-31 | $28.82 Million | $-55.96 Million | -1.942x | -346.47% |
| 2023-12-31 | $76.51 Million | $-33.27 Million | -0.435x | +28.54% |
| 2022-12-31 | $68.49 Million | $-41.68 Million | -0.609x | -88.94% |
| 2021-12-31 | $111.37 Million | $-35.88 Million | -0.322x | -74.92% |
| 2020-12-31 | $149.43 Million | $-27.52 Million | -0.184x | -144.72% |
| 2019-12-31 | $-30.64 Million | $-12.62 Million | 0.412x | -14.45% |
| 2018-12-31 | $-17.80 Million | $-8.57 Million | 0.481x | -- |
About Spruce Biosciences, Inc. Common Stock
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating… Read more